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ABSTRACT 
 
Cancer creates one of the most significant public health problems not just 
in the United States, but worldwide. While one of the most effective treatment 
protocols for cancer is chemotherapy, the conventional agents used in 
chemotherapy affect normal tissue as well as cancerous tissue. This thesis reports 
the development of a new cancer drug delivery system based on nanoparticles, 
which is designed to target tumor sites better than previous practices.  
 
In this study, nanoparticles coated with cathepsin D-specific peptides were 
developed as a vehicle for the targeted delivery of the cancer drug doxorubicin 
(DOX) to treat breast malignancy. Cathepsin D, a breast cancer cell secretion, 
triggers the release of DOX by digesting the protective peptide-coating layer of 
nanoparticles. Ultrasound imaging successfully detected fabricated nanoparticles 
in both in vitro conditions and in vivo mouse cancer models. Cell viability 
experiments were conducted to determine the efficacy of biomarker activation 
specific to breast cancer cell lines. These experimental results were compared 
with the outcome of a viability experiment run on non-cancerous cells. Viability 
decreased in human breast MCF7 cancer and mouse breast 4T1 cancer cells with 
no effect on fibroblast 3T3 non-cancerous cells. The next step was to obtain a 
real-time video of nanoparticle flow in mouse models using in-vivo ultrasound 
imaging. In vivo fluorescence imaging enabled the examination of cancerous 
mice injected with the drug-carrying nanoparticles. Results showed the 
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distribution of nanoparticles in subject mice bodies, with concentrations in 
bladder and tumor sites. This finding suggests that nanoparticles are able to 
specifically target tumor tissues. It also suggests nanoparticles are resistant to 
nonspecific disintegration of peptide coating and consequential system drug 
release.  Thus, the results of this work can be of great value for the development 
of more effective cancer treatment methods.   
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CHAPTER 1: INTRODUCTION 
 
According to the International Agency for Research on Cancer (IARC), 
cancer caused 7.6 million deaths worldwide in 2008 and currently one in every 
four deaths in the United States is due to cancer [1]. Chemotherapy is widely used 
for cancer treatments despite the many side effects it imposes to a patient’s health. 
High doses of chemotherapeutic agents are required to treat large tumors; 
however, their toxicity limits the dosage of chemotherapeutic drugs that can be 
given to a patient, resulting in suboptimal treatment of cancer. 
 
 
1.1. Nanotechnology and Cancer Treatment 
Several strategies have been proposed to target cancer cells, mostly based 
on biodegradable polymeric particles, which have attracted considerable attention 
due to their stability [2], versatility of surface modification [3], and potential for 
different drug release characteristics [4, 5, 6]. However, in these studies, although 
delivery efficiency increases with particle drug carrier, off-target drug release still 
exists due to the fast drug release of nanoparticles during circulation. One of the 
promising strategies, conjugating nanoparticles with antibodies that detect tumor-
associated antigens, showed successful results for in vitro screening [7]. However, 
despite these encouraging results in vitro, the in vivo application might be 
restricted due to weak linkage stability and potential immunogenicity after 
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repeated injections [8]. Thus, the problem of finding an effective nanocarrier is 
still unresolved despite the aforementioned strategies.  
In this project, we report using innovative nanoparticle drug capsules, 
through which the chemotherapy drug release can be triggered and tuned by 
nothing but the biomarker protease enzymes that are secreted in breast cancer 
cells and their extracellular matrix. That is to say, the cancer drug is only released 
in the vicinity of breast cancer tissue and the release dosage is inherently 
proportional to localized cancer status.  Drug release from nanoparticle capsules 
in living breast cancer animal models can be monitored in real time through the 
use of high-resolution ultrasound imaging and fluorescence imaging to 
demonstrate the targeted release localized near the breast tumors. The main 
objective of the study described in this thesis is to develop an innovative design of 
drug delivery nanocapsules that are activated by cancer-specific biomarker 
enzymes for high-precision cancer chemotherapy. This thesis discusses work done 
towards this goal, particularly it discusses imaging results and evaluation of the 
effects of nanoparticles in in vivo and in vitro conditions.  
 
 
1.2. Scope of the Research 
1.2.1. Unique Aspects 
Currently available strategies based on biodegradable nanoparticles 
impose early polymer degradation and risk of off-target drug delivery. In this 
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study, a unique design of nanocarriers prevents polymer degradation before the 
nanocarriers reach the tumor sites, largely due to a conjugated peptide layer on the 
nanocarrier surface that prevents the drug from being released early. Additionally, 
although there have been studies that showed encouraging results in terms of off-
target drug release, nanoparticles still impose toxicity due to the silicon nature of 
the nanocarriers used in the studies [9, 10, 11]. This thesis, however, discusses the 
work done with nanoparticles made of biodegradable and non-toxic material. 
Finally, the time-lapse drug delivery and release dynamics information acquired 
from ultrasound and fluorescence imaging is extremely valuable for breast cancer 
chemotherapy studies. Suitability of proposed nanoparticles for ultrasound 
detection makes them a perfect combination of contrast agent and cancer drug 
carrier in one. 
 
1.2.2. Impact of Study 
This study directly addresses the most challenging problem in standard 
chemotherapy, off-target drug release, and advances a new potential cancer 
treatment. Proof of the concept opens the door to a more precise and effective 
method of cancer treatment that does not impose all the side effects traditional 
chemotherapy carries. Technologies originated from this concept could be applied 
to available chemotherapy drugs on the market and can make use of the drugs that 
are much safer and more efficient than those that are currently used in breast 
cancer treatment. By varying the substrate peptide sequences used for 
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nanoparticle coating, different cancer biomarkers can be targeted and the hybrid 
drug nanocapsule may be tailored for different subtypes of breast cancers for 
personalized medicine and therapy. Thus, this technology opens broad 
opportunities for a new generation of cancer treatments. 
 
 
1.3. Overview 
This work focused specifically on breast cancer malignancy. In order to 
achieve the final goal of the work - to show the effect of nanoparticles on breast 
cancer tumors in in vitro and in vivo conditions - the project comprised four main 
stages. Before the main study was conducted, in order to determine the best 
method for effective coating of nanoparticles, preliminary studies of conjugation 
techniques for small molecules were carried out. After the preliminary work came 
the main part of the study: the fabrication of peptide-coated and drug-loaded 
nanoparticles. The second stage of the study included evaluation of effects of 
nanoparticles on cancer cells in in vitro conditions. Finally, the concluding stage 
consisted of in vivo and in vitro imaging of biomarker activated nanoparticle 
capsules in animal models.  
 
This thesis is broken up into several chapters that describe relevant stages 
of the study. Chapter 2 discusses the background information about existing 
problems in nanoparticle drug delivery and introduces the concept behind the 
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design of proposed nanoparticles. Chapter 3 discusses the methods used in the 
research completed for this thesis. It describes the parameters examined and 
outputs collected during the various stages of this work. Chapter 4 reviews the 
results and analysis obtained from the experiments described in Chapter 3. It 
reflects on and explains the outcomes of the research done during each stage of 
the study. Chapter 5 summarizes the main results and establishes their relevance 
to our study’s primary objective. This chapter then continues with future 
recommendations and perspectives for this research project.  
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CHAPTER 2: THEORY AND CONCEPT OF THE WORK 
 
2.1. Standard Chemotherapy and Its Limitations 
Cancer chemotherapy was first successfully used in the 1950s when 
nitrogen mustard, previously used as a war gas, was found to be useful in 
inhibiting tumor growth [12]. However, due to its toxicity, chemotherapy with 
anticancer drugs took until the 1960s to be widely applied and it started to gain 
popularity in 1970s as a means to cure or inhibit the growth of certain types of 
cancers [12]. Currently there is an immense number of different anticancer agents 
available for chemotherapy; however, drugs that are more effective tend to be 
more toxic. As a result, off-target cancer drug delivery causes serious side effects 
and systemic damage to a human body going through chemotherapy. For 
example, doxorubicin (DOX), the most effective and widely used anticancer drug, 
is reported to cause adverse effects including nausea, vomiting, anorexia and heart 
damage (cardiotoxicity), which considerably limit its applicability [4, 13, 5]. 
Therefore, prevention of systemic drug release is crucial to improving current 
chemotherapy. With the emerging field of nanotechnology and huge progress in 
nanoparticle technology, development of nanoparticles of biodegradable polymers 
as an effective drug delivery vehicle for chemotherapy has become a new 
breakthrough among alternative methods of cancer treatment.  
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2.2. Nanoparticle Drug Delivery and Its Limitations 
In the past few decades, research has emerged on the development of 
targeted drug delivery to cancer cells using nanoparticles.  Nanoparticles, which 
have a small size suitable for intracapillary passage, provide an ideal solution for 
the mentioned challenge of current chemotherapy: toxicity of chemotherapeutics 
[14, 15, 16]. Additionally, nanoparticles can provide a controlled and targeted 
way to deliver the encapsulated cancer drugs and consequently provide high 
efficacy and minimized, or even completely mitigated negative side effects of off-
target drug release [17, 18, 19]. However, despite the emerging and promising 
research done in in vivo therapy based on nanoparticles, there are still many 
difficulties to overcome in order to create an effective vehicle for targeted drug 
delivery. Some of the important challenges current nanoparticle-based drug 
delivery research encounters are the conjugation of developed nanoparticles with 
host molecules, multiple loading functionality, biodegradability, and toxicity [20, 
21]. Additionally, 40% of anticancer drug candidates suffer from poor solubility 
due to crystal phase formations on nanocarriers [22]. Under intense study, porous 
silicon films and microparticles have been proposed for biomedical applications 
[23, 24, 25, 26, 27], showing high loading and releasing capacity, in vivo 
monitoring, and easy chemistry. However, these studies were carried out on 
micrometer-sized particles, while nanoparticles with diameters between 20 and 
100 nm have been speculated to be ideal for cancer therapy [21, 28-30]. Off-target 
drug release of proposed particle carriers still exists due to the fast drug kinetics 
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during circulation. Additionally, for effective nanoparticle-based systems, it is 
essential to monitor drug delivery to targeted sites and verify the efficacy of the 
encapsulating peptide or antibody coating. However, it is difficult to monitor drug 
carrier transport due to lack of sufficient contrast of existing nanoparticles for 
current monitoring systems. The whole field of cancer treatment can be 
substantially improved by engineering such drug nanocarriers that can provide 
better contrast for imaging studies, prevent systemic drug release and achieve the 
correct specificity.  
 
 
2.3. Concept of Novel Nanoparticles for Targeted Drug Delivery 
In this study, we report a novel gelatin nanoparticle carrier for the targeted 
delivery of DOX to treat breast malignancies, which avoids problems of early 
nonspecific dissolution and off-target drug release and is suitable for high-
resolution ultrasound and fluorescence imaging in animal models. The versatile 
nanotechnology here could be applied for treatment of different kinds of cancer 
with the change of biomarker specific peptides. A schematic diagram of the 
chemotherapeutic drug delivery vehicle is shown in Fig. 1.  
 
The nanoparticle core was fabricated by the Electric Field Assisted 
Precision Particle Fabrication (E-PPF) method using acidic gelatin, loaded with 
DOX [31, 33].
 
The resulting nanospheres were coated with a high-density peptide 
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layer, the hydrolysis of which is catalyzed by cathepsin D, a specific biomarker 
protease hypersecreted by breast cancer cells. Thus, the core is protected from 
general proteolysis, wherein DOX is safely contained, until the digestion of the 
peptide shell is catalyzed by the secretory protease enzyme cathepsin D in the 
proximity of breast cancer cells. As the peptide shield is removed, gelatin is 
exposed to general proteases abundant in all cell secretions, triggering the release 
of DOX. As a result, the drug is released only in the vicinity of the target cancer 
cells and its release dosage is controlled by the localized secretory protease 
concentration. Because of the low presence of targeted protease in benign tissues, 
the peptides covering the nanocapsule surface remain intact and the drug inside 
the nanocapsule is well contained. By these means, a most effective 
chemotherapy may be achieved with minimal side effects.  
 
Fig. 1 Illustration of gelatin nanoparticle drug carrier protected by 
protease substrate peptides. 
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CHAPTER 3: METHODS 
 
3.1. Preliminary Work: Conjugation Procedures 
Chemical structure of the drug-loaded nanoparticles plays an important 
role in determining the adhesion of nanoparticles to and their interaction with 
cells. Conjugation of molecules to and their amount on the surface of 
nanoparticles have a significant effect on drug encapsulation efficiency, since the 
coating serves as a barrier to protect the leakage of the drug from the 
nanoparticles. Better conjugation of molecules to the surface prevents the early 
degradation of nanoparticles in the system, improving the targeted drug delivery 
efficacy. Therefore, prior to utilizing the peptide coating design, which is further 
discussed in the following subsections, various conjugation techniques and 
procedures were investigated as a preliminary stage of this project.   
 
3.1.1. Antibody-Antigen Conjugations 
The conjugation of small molecules (SM) to proteins is widely used in 
medical diagnostics and is valuable for nanoparticle drug delivery systems. 
Labeled antibodies and antigens are required in many diagnostic techniques. 
During this stage of the work, we experimented with enzyme-linked 
immunosorbent assay (ELISA) protocol conjugation. Polycarbonate surface was 
chosen as a substrate for antibody-antigen conjugation experiments for potential 
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usage of these results for another study [32]. Several strategies for activation of 
polycarbonate surface have been used.  
 
Polylysine treated surface. In order to create a layer that is welcoming to 
conjugation of SMs, particularly Bovine Serum Albumin (BSA) (Sigma-Aldrich) 
molecules, a CD surface was treated with polylysine (Sigma-Aldrich). Figure 2 
shows the schematics of ELISA performed on a compact disk. First, 0.5 ml of 2 
mg/mL polylysine was applied to the CD surface and incubated in humid 
conditions for 24 hrs. After washing the surface, 0.5 ml of 1% glutaraldehyde 
(Sigma-Aldrich) was applied to the surface and incubated for 2 hrs. 
Glutaraldehyde (GA) is a cross-linker that has a carboxyl group on both ends. The 
carboxyl group of GA bonded with amine groups of previously applied polylysine. 
The other end of the GA was conjugated with an amine bond of primary antibody, 
Anti-Bovine Serum Albumin antibody (Abcam), that was applied as the next step 
in the experiment, and the layer was incubated for 2 hrs. This incubation step 
ensures the immobilization of antibodies to the surface so that antibody-specific 
molecules could be used for binding. Washing with PBS accompanied each 
incubation step. For the conjugation experiment, immobilized antibody specific 
antigen BSA and its secondary antibody FITC-IgG (Sigma-Aldrich) were used. 
Secondary antibody FITC-IgG that is specific to BSA molecules was applied for 2 
hrs, after the BSA molecules were conjugated with the primary antibody. FITC-
IgG has a fluorescence tag that emits fluorescence when the    
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conjugation between antibody and antigen occurs. Due to emitted fluorescence 
the whole conjugation could be confirmed via fluorescence microscopy. 
 
 
 
Oxygen plasma treated surface. Another way of immobilizing the proteins 
on the polycarbonate surface could be creating an abundance of –OH bonds and 
having antibodies bind to the polycarbonate surface directly without the use of the 
GA cross-linker. For this purpose, our substrate was treated with oxygen plasma, 
 
 
  
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
  
 
 
  
  
  
 
 
 
 
 
 
CD 
Primary BSA 
Antibody 
Glutaraldehyde 
layer 
Polylysine layer 
FITC-IgG 
Antigen 
(BSA) 
Fig. 2 Schematics for antibody-antigen conjugation to polycarbonate surface 
of a compact disk 
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and primary antibody-antigen-secondary antibody conjugation was performed 
following the previously described procedure for the ELISA experiment.  An 
advantage of this method is that it allows skipping the glutaraldehyde step, since 
proteins could bind to the oxygen-treated surface directly. A limitation that we 
observed in this experiment was that oxygen plasma applied to the surface of the 
CD was unstable and conjugation had to be done in short periods of time. Since 
the incubation steps in ELISA were lengthy, treating with oxygen plasma was a 
problematic solution to creating bonds on the polycarbonate surface. 
 
Reactive Ion Etching activated surface. Previous studies have reported the 
usage of reactive ion etching (RIE) for preparing substrate materials for protein 
arraying applications that involve fluorescence-based detection [34]. In RIE, 
plasma etches the surface of a substrate using both chemically reactive species 
and ion bombardment. The resulting volatile byproducts get removed in vacuo 
during the process. RIE process enhances the roughness and porosity of the 
polycarbonate surface, thereby facilitating the protein adsorption on the surface of 
RIE-etched polymers [34]. Additionally, there is evidence, such as the enhanced 
surface hydrophilicity, of chemical effects that may have improved the retention 
of adsorbed protein on the etched surface [34]. However, in order to minimize the 
physical damage to the substrate that is typically caused by ion bombardment, in 
this study all parameters had to be carefully chosen for effective RIE-activation of 
the polycarbonate surface. In order to RIE-activate the CD surface, the following 
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parameters were used: 30% RF power, 80% oxygen, 20% CF4, 100 mTorr 
throttle pressure. Etching time varied from 20 to 40 minutes for this set of 
experiments. After RIE-activation, standard procedure of sandwich ELISA could 
be performed. Additionally, a simple antibody-antigen procedure could be applied; 
however, in the choice of antibodies, it is important to use fluorescently labeled 
antibodies for conjugation detection purposes.  
 
Glutaraldehyde conjugated blue microparticles. Results of this 
conjugation experiment were published elsewhere as an application for 
microparticle counting using a standard CD drive [32]. Figure 3 shows the 
schematics behind the immobilizing BSA molecules on the polycarbonate surface. 
First, the surface of a standard CD is treated with polylysine, and glutaraldehyde 
modified microparticles that are coated with BSA molecules are incubated on top 
of the polylysine layer. For glutaraldehyde conjugation of microparticles, 10 µm 
blue polystyrene microparticles (Polysciences, Inc.) were conjugated with 8% 
glutaraldehyde. The conjugation protocol is described elsewhere [32]. One ml of 
glutaraldehyde modified blue microparticles was incubated with BSA antibody 
solution for 10 hrs. This solution was then incubated on the polylysine-activated 
CD surface for 3 hrs and was followed by washing.  
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Fig. 3 Schematics of immobilizing the antibody conjugated polystyrene microparticles 
to CD surface. 
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3.2. Fabrication and Characterization of Drug Nanocarriers 
Following the preliminary experiments for conjugation techniques of 
proteins applied to different surfaces, which are described in the previous chapter, 
fabrication of nanoparticles was established as the first main stage in this study.  
 
3.2.1. Fabrication, Cross-linking and Drug loading 
Gelatin (225 g bloom, BioReagent) polymer nanoparticles were prepared 
by the E-PPF [33]. In order to create cross-linking moieties on the surface of 
nanoparticles for consequent conjugations with peptide (which will be described 
in the next subsection), fabricated gelatin nanoparticles were cross-linked using 
GA that forms carboxyl groups on the surface of the nanoparticles. Fabricated 
nanoparticles were imaged with high-resolution ultrasound to show that they can 
provide sufficient contrast to monitor the drug transport in the consequent in vivo 
experiments.  
 
To prepare nanocapsule carriers from the fabricated nanoparticles, DOX 
molecules (Sigma-Aldrich) were loaded into the polymer matrix through 
diffusions in excess drug solutions. Upon inward diffusion, the drug molecules 
were ionically impregnated to the polymer matrix so that unless attacked by an 
enzyme, they may not be released.  
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A standard parameter used for characterizing nanoparticles in drug 
delivery studies is swelling ratio, which could be characterized by using equation 
(1). Swelling ratio was calculated for fabricated nanoparticles using the 
dimensions of dry and wet particles. 
 𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔  % = 100(𝑊!"# −   𝑊!"#)/𝑊!"!        (1) 
 
where Wwet and Wdry are the weight of the wet and dry sample, respectively. Wet 
nanoparticle samples were prepared by immersing dry nanoparticles in a 
phosphate buffer saline (PBS) (Sigma-Aldrich) solution at room temperature for 
24 hrs. 
 
3.2.2. Coating the Nanoparticle Surface 
In order to keep the drug inside the capsule, the peptide strands were 
synthesized and a cross-linker moiety group was grafted at the terminal. Peptides 
were attached through covalent bonding between the cross-linking amine moiety 
groups at the peptide terminal and the carboxyl groups on the surface of the 
gelatin nanoparticles, which were previously formed via glutaraldehyde.  In order 
to catalyze the conjugation of peptides to the nanoparticle surface, catalyst EDC-
NHS (Sigma-Aldrich) was successfully employed. The specificity of the designed 
peptide substrate to the cathepsin D enzyme secreted by breast cancer cells was 
examined via the fluorescence emission from the terminal methoxycoumarin 
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(MCA) fluorophore molecule. The fluorescence was quenched by the 
dinitrophenyl (Dnp) molecule before the proteolytic reaction due to near field 
fluorescence energy transfer between the MCA fluorophore and Dnp quencher 
molecule.  
 
 
3.3. In Vitro Chemotherapy 
 
3.3.1. Cell Culture 
To evaluate target cell specificity, nanoparticle mediated chemotherapy on 
three different types of cells was carried out. MCF7 human mammary 
adenocarcinoma, 4T1 mouse mammary carcinoma, and 3T3 mouse fibroblast 
were chosen (all from ATCC, Manassas, VA) for the experiment. ATCC-
formulated Eagle’s Minimum Essential Medium with 0.01 mg/ml bovine insulin, 
10% final bovine serum (FBS) was used as a culture medium for MCF7, while 
3T3 Swiss mouse fibroblast cells (ATCC) were cultured using ATCC-formulated 
Dulbecco’s Modified Eagle’s Medium mixed with bovine calf serum to a final 
concentration of 10%. 4T1 mouse breast cancer cells were cultured using RPMI-
1640 media mixed with 10% FBS. All media were filtered using a 0.22 µm 
vacuum filter for sterilization. The cells were added to the cultured media and 
then kept in 75 sq. cm flasks for culturing in incubator with 5% carbon dioxide at 
37.0 °C.  
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3.3.2. Effect of Drug Nanocarriers on Cell Viability 
Prepared cell cultures were incubated with 2x106 drug loaded 
nanoparticles coated with peptide strands mixed in phosphate buffer solution 
(PBS) for 7 hrs. Optical images were taken every 2 to 3 hr and cell viability was 
measured at different time points.  
 
Additionally, a MTT cell proliferation assay (ATCC) was carried out for 
cultured human breast MCF7 and mouse breast 4T1 cancer cells. This assay 
provides a reliable and quantifiable means of measuring the absorbance values of 
cell populations through spectrophotometry. Each 30,000 cells/mL solution of 
4T1 cells and 38,000 cells/mL solution of MCF7 cells were placed in 2 and 4 
wells of 96-well plates in equal amounts for each cell line, respectively. While 
half of the wells for each cell line were treated with drug carrying nanoparticles, 
the remaining half was incubated without nanoparticles for control measurements. 
Cell viabilities of treated MCF7 and 4T1 cells were assessed after incubation time 
using the MTT proliferation assay procedures. The results were compared to 
viabilities of the cells that were incubated under the same conditions, but without 
any addition of drug loaded and peptide coated nanoparticles.  
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3.4. In Vivo Chemotherapy 
In order to test fabricated nanoparticles in in vivo conditions, we 
conducted extended animal studies. For this stage of the study, the experimental 
protocol was approved by the Institutional Animal Care and Use Committee of 
the University of Illinois and satisfied all campus and National Institutes of Health 
rules for the humane use of laboratory animals. Animals were housed in a facility 
approved by the Association for Assessment and Accreditation of Laboratory 
Animal Care (Rockville, MD) and provided food and water ad libitum. 
 
3.4.1. Animal Models 
Female 5-week-old athymic nude mice (19-23 grams on arrival) were 
ordered from Harlan Laboratories and individually housed in separate cages. For 
tumor inducement, mice were anesthetized under isofluorane (2% isofluorane, 2% 
oxygen flow rate) and subcutaneously injected with 100 µL of media containing 
1x105 4T1 cells in the lower abdominal mammary gland. Following injection, 
mice were monitored every 1-3 days. Mice that did not display tumor growth after 
6 weeks were reinjected under the lower right abdominal glands. Tumors were 
allowed to grow up to a maximum size of 10 mm before exposure. In vivo whole-
body imaging studies, which are described in the consequent sub-chapter, 
followed similar anesthesia. 
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3.4.2. In Vivo Ultrasound and Fluorescence Imaging  
For in vivo ultrasound detection, nude mice (Harlan, Indianapolis, IN) 
weighing 19-21 g were injected via the lateral tail vein with 100 µL of saline 
solution containing 2x109 nanoparticles per mL that ranged between 200 and 900 
nm in diameter. Real-time video of nanoparticle flow in the superior vena cava 
was captured starting from the injection time using a VisualSonics Vevo 2100 
High Frequency Ultrasound Imaging System, indicating the potential application 
of the drug-carrying nanoparticles in serving as ultrasound imaging contrast 
reagents.   
 
Along with ultrasound imaging, due to a fluorescent nature of DOX, 
mouse models injected with fabricated nanoparticles were imaged with 
fluorescence microscopy. Following the method described in the previous 
subsection for tumor inducement into nude mice, animals were tumor induced 
before fluorescence imaging. These 4T1 tumor mice were then injected with 100 
µL of saline solution containing 2x109 peptide coated drug nanocarriers.  Due to 
the naturally fluorescing nature of DOX, fluorescence images of the injected and 
control mice were obtained for accessing the distribution of the drug in the mouse 
body after injection. Based on the DOX fluorescent profile, an excitation of 470 
nm and emission of 590 nm were used. 
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CHAPTER 4: RESULTS AND DISCUSSIONS 
 
4.1. Gelatin Nanoparticles 
 The scanning electron microscope (SEM) image in Fig. 4(A) and optical 
image of particles in saline solution (Fig. 4(B)) show that the particles fabricated 
by the E-PPF method are spherical and uniform in size. 
The swelling ratio, defined as the ratio of diameters of wet (1.62 µm) and 
dry (0.9 µm) particles, was 1.8. Figures 4(C) and 4(D) show optical images of dry 
and DOX-loaded nanoparticles after centrifugation and washing.  
 
The specificity of the designed peptide to cathepsin D was examined via 
fluorescence emission from the terminal MCA fluorophore molecule on the 
peptide strand. Figure 5 schematically illustrates gelatin particles conjugated with 
peptides containing a Leu-Phe-Phe-Arg-Leu sequence, which can be recognized 
by cathepsin D, an aspartic protease enzyme prominent in breast malignancies 
[18]. Once hydrolysis of the peptide is catalyzed by cathepsin D, the peptide 
substrate fluoresces as an indicator of the proteolytic activity of the peptide 
coating layer on the nanoparticle surface. When the peptide-coated particle loaded 
with DOX is incubated, respectively, with purified cathepsin D and with the 
MCF7 breast cancer cell media, the fluorescence intensity, as shown in Fig. 6, 
increases. 
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Fig. 4 (A) Scanning electron microscope images of gelatin submicron 
particles; (B) Optical image of gelatin particles after swelling in saline solution 
(200 nm – 5 µm); (C) Optical image of dry nanoparticles; (D) Nanoparticles 
loaded with cancer drug (DOX) after centrifugation. The scale bar represents 
10 µm. 
 
(A) 
(B) 
(C) 
(D) 
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  D-­‐Arg-­‐NH2-­‐COOH-­‐ 
 
 
 
 
 
 
 
 
  
 
 
 
Hydrolytic	  
Cleavage  
 
 
 
 
 
 
   
 
 
 
 
  Mca-­‐Gly-­‐Lys-­‐Pro-­‐Ile-­‐Leu-­‐Phe  
Phe-­‐Arg-­‐Leu-­‐Lys(Dnp)-­‐D-­‐Arg-­‐NH2-­‐COOH-­‐  
Fig. 5  Schematic illustration of peptide-conjugated nanoparticles. The peptide 
sequence is shown. The peptide can be hydrolyzed at the Phe-Phe bond by 
cathepsin D enzymes and then shows the fluorescence. 
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This observation indicates active proteolytic reactions on the particle 
surface. On the other hand, the blue fluorescence intensity remains unchanged 
when the particles are incubated with nontargeted protease enzymes, e.g., 
collagenase 1A and nontargeted human cell lines (e.g. Hela cells), which strongly 
indicates the specificity of the peptide layer to the targeted cancer biomarker, in 
this case cathepsin D.  For 3T3 mouse fibroblast cell secretions, possibly due to 
the nonspecific proteolytic reactions of the peptides, the peptide fluorescence 
intensity is also elevated but the elevation level and sustainability are significantly 
lower than those for MCF7 mammary adenocarcinoma cells. Better design of 
peptides with higher specificity also will help to minimize the nonspecific 
proteolytic reactions. 
 
 
 
Fig. 6 Peptide fluorescence intensity under different 
incubated conditions.  
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controls. Nanoparticles incubated with 4T1 cells significantly reduced the cell growth in the span 
of 7 hr (Fig. 4C), but did not affect the growth rate of 3T3 cells (Fig. 4C). The number of 3T3 
fibr lasts increased due to cell proliferati , which indicates negligible cytotoxicity to these 
nontargeted cells. In contrast, the number of 4T1 cells decreased dramatically by more than 80% 
after 5 hr and kept this downward trend temporally (Fig. 4C). 
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Fig. 3 Peptide hydrolysis and DOX drug release from the 
gelatin nanoparticles. (A) Schematic illustration of 
peptide-conjugated nanoparticles. The peptide sequence 
is shown. The peptide can be hydrolyzed at Phe-Phe bond 
by Cathepsin D enzymes and then show fluorescence. (B) 
Peptide fluorescence intensity under different incubated 
conditions.  
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4.2. Targeted Chemotherapy on Breast Cancer Cells 
The morphology of peptide-coated nanoparticles cultured with three 
different cell lines was examined along with the number of resulting viable cells. 
MCF7 mammary adenocarcinoma cells and 4T1 mouse mammary carcinoma 
cells were specifically chosen to prove the peptide specificity to cathepsin D 
secreted by these cells, while 3T3 mouse fibroblasts were used as controls. 
Nanoparticles incubated with 4T1 cells significantly reduced the cell growth in 
the span of 7 hr (Fig. 7), but did not affect the growth rate of 3T3 cells (Fig.7). 
The number of 3T3 fibroblasts increased due to cell proliferation, which indicates 
negligible cytotoxicity to these nontargeted cells. In contrast, the number of 4T1 
cells decreased dramatically by more than 80% after 5 hr and kept this downward 
trend temporally (Fig. 7). 
The number of MCF7 cells, although with some oscillation temporally, 
eventually decreased to 50% of its initial concentration after 7 hr. These results 
demonstrate that the peptide coating enables the specificity of particle drug 
delivery system to only target cancer biomarkers and associated tumor cells. 
Results of these experiments using mice and human breast cancer cells are shown 
in Fig. 8 and 9. Cell concentrations of treated and untreated MCF7 and 4T1 cells 
were assessed after a 2-hr incubation time for each cell line.  
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Figures show that cell viability was significantly reduced for cells 
incubated with nanoparticles, while control cells that were untreated with 
nanoparticles continued their growth, reinforcing the same result obtained in the 
discussed Fig. 7. While the concentration of 4T1 cells decreased from 30,000 to 
26,000 cells/mL by the end of incubation time, the concentration of control 4T1 
cells remained unaffected, increasing to 34,000 cells/mL Analogous trends for 
MCF7 cell growth were obtained. Thus, results demonstrate significant effects of 
drug-loaded nanoparticles conjugated with peptides on breast cancer cell viability. 
Figures 8 and 9 show that viability of nanoparticle treated human and animal 
breast cancer cells decreases, unlike untreated control cells.  
 
 
Fig. 7 Cell counting for 3T3 (control), 4T1 and MCF7 cells in 7 hr duration. 
Viability of 3T3 cells treated with nanoparticles increases, unlike mouse cancer 
4T1 and human breast cancer MCF7 cells viabilities that significantly decrease 
after incubation with nanoparticles. 
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Fig. 8 Comparison of number of viable cells for MCF7 cells treated and 
untreated with nanoparticles.  
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Fig. 9 Comparison of number of viable cells for 4T1 cells treated and 
untreated with fabricated nanoparticles. 
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4.3. In Vivo Ultrasound Imaging of Nanoparticles 
Gelatin nanoparticles were injected into control mice via the lateral tail 
vein and real-time video of the superior vena cava was taken immediately after 
the injection. Snapshots of the particles passing through the vein located near the 
mouse heart are shown in Fig. 10(A) and 10(B). Figure 10(A) shows the vena 
cava before introducing the particles into the body, while Fig. 10(B) shows gelatin 
particles passing through the vein. Results suggest that the proposed nanoparticles 
can act as imaging contrast agents, facilitating in vivo high-resolution ultrasound 
imaging. This observation could be due to the swelling characteristic of the 
nanoparticles, which causes the formation of air gaps and free pores, giving them 
distinctive acoustic impedance.  As a result, the particles can act as reflective 
mediums for ultrasound waves, allowing in vivo ultrasound detection, tracking of 
particle flow, and distribution in real time.  
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Fig. 10 High-frequency ultrasound images of the blood vessel in the heart of a 
nude mouse during the injection of nanocapsules. Ultrasound imaging of vena 
cava vessel (A) before and (B) several seconds after the injection of particles via 
the tail vein into the mouse body. The nanocapsules in flow can be clearly 
identified and equivalently act as imaging contrast agents. 
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4.4. Targeted Chemotherapy on Breast Cancer Mouse Models 
The fluorescence nature of DOX used for preparation of the proposed 
nanoparticles allowed us to use fluorescence imaging techniques for monitoring 
the distribution of nanoparticles in vivo. Fluorescence imaging was performed to 
demonstrate peptide coating stability and nanoparticle drug release specificity to 
biomarkers secreted by tumor sites under in vivo conditions. As previously 
described both mice with and without cancerous growths were injected with 100 
µL of fabricated particles mixed in saline solution and underwent whole body 
fluorescence imaging using a small animal fluorescence imaging system. The 
Fig. 11 (A) Fluorescence image of control cancer-free mouse not injected with 
DOX nanocapsules; (B) Fluorescence image of control cancer-free mouse model 
after the injection of drug loaded nanoparticles coated with peptide layer; (C) 
Fluorescence image of a cancerous mouse model with 4T1 breast tumor after 
injection of nanoparticles.  
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 with DOX Nanocapsule IV 
Injection 
bladder 
Tumor 
Control Mouse (no tumor) 
 without DOX Nanocapsule IV 
Injection 
Control Mouse (no tumor) 
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fluorescence images are overlaid on the bright field images to identify the 
locations of nanocapsules present in the mice (Fig. 11). The middle image in Fig. 
11 shows that most of the particles are filtered out and end up in the bladder, 
while the image of the 4T1-tumor mouse displays that proposed nanoparticles 
concentrate not only in the bladder, but also reach the tumor site located at the 
right side of the mouse body. Evidently, DOX fluorescence is strong in the tumor 
and at the locations near the tumor, suggesting the targeted delivery through the 
nanocapsules. Thus, the concentrated distribution of drug carrying nanoparticles 
in the 4T1 tumor supports the hypothesis that introduced particles are biomarker 
activated through peptide encapsulation.  
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CHAPTER 5: CONCLUSION AND FUTURE STUDIES 
 
5.1. Conclusion 
In this study, nanoporous gelatin nanoparticles were fabricated as a 
vehicle for high-specificity and targeted drug delivery to breast cancer cells. 
Chemotherapeutic DOX drug molecules were loaded in the gelatin nanocarrier 
and coated with protective peptide strands to prevent the early degradation and 
nonspecific drug release. Release of drug immobilized by cross-linked gelatin, the 
loading efficiency of which can be optimized by controlling the cross-linker 
concentration, is triggered only by the biomarker protease enzyme cathepsin D 
secreted by the breast cancer cells. In comparison with the chemotherapy with 
free-form drug or uncoated nanoparticles, our peptide-coated nanospheres can 
significantly improve the specificity of cancer chemotherapeutic drug delivery 
and mitigate the adverse side effects due to the off-target drug release. Varying 
the peptide sequences for surface coating can also target different cancer 
biomarkers, the nature of which depends on cancer type. Thus, hybrid drug 
carriers may be tailored for different subtypes of cancers for personalized 
medicine and therapy.  
 
The nanoscale size of particles allowed us to extend the studies to in vivo 
drug delivery. We achieved high contrast for fabricated gelatin nanocarriers 
during in vivo ultrasound imaging to monitor the nanocarrier transport after its IV 
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injection. The targeted drug delivery scheme was successfully demonstrated in 
vitro and in vivo for breast cancer malignancy with fluorescence imaging 
techniques. We anticipate that with higher specificity and stability of our peptide 
conjugated drug nanocarriers, systemic drug release and off-target drug delivery 
problems can be addressed to remove adverse side-effects of current cancer 
malignancy treatments.  
 
 
5.2. Recommendations for Future Studies 
In Chapter 3 we presented methods for in vivo whole body fluorescence 
imaging experiment, results of which in Chapter 4 showed the specificity of 
nanoparticles to tumor sites. DOX that was loaded in the particles was released in 
the vicinity of the tumor site and degraded DOX was filtered out in the organs of 
an animal. In vivo fluorescence imaging can be improved by investigating in vivo 
chemotherapy efficiency. Running these experiments again, but this time with the 
purpose of monitoring the tumor shrinkage level, which is treated with 
nanoparticles, will be a good step to move this project forward.  
 
Looking broadly at the overall future perspectives, the work reported in 
this thesis shows the pathway toward the development of smart nanoparticle drug 
carriers. The drug delivery dosage is fine-tuned by the localized biomarker 
concentration and the chemotherapy drug is released in the vicinity of the tumor 
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rather than upon the physical binding with the tumor. All these unique properties 
make the reported enzymatically activated nanoparticle drug carrier a better one 
than antibody based carriers by providing lower systemic release and high 
delivery efficiency. The targeted drug delivery in the coming decade will rely on 
nanoparticle drug carriers that actively search for potent cancer cells, diagnose the 
cell condition and decide drug delivery dosage and rate autonomously. After drug 
delivery, the nanoparticle drug carrier can dissolve itself and be cleared out of a 
body.  Negative side effects can be reduced to nearly zero and the precision drug 
delivery can result in optimized, rapid and effective cancer chemotherapy.  
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